CIK 0001420565
- Non-accelerated filer
- Smaller reporting company
Rein Therapeutics, Inc.
Sign in to watch- Ticker
- RNTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 134196017
- Phone
- +1 737-802-1989
- Business address
- 12407 N. MOPAC EXPY., SUITE 250 #390, AUSTIN, TX, 78758
- Former names
- Aileron Therapeutics, Inc., AILERON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-07-05 | Kapnick Scott Director | Conversion · Series E-2 Preferred Stock | −612,002 | 0 | ||
| 2017-07-05 | Kapnick Scott Director | Conversion · Series E-3 Preferred Stock | −1,266,130 | 0 | ||
| 2017-07-05 | Kapnick Scott Director | Conversion · Series F Preferred Stock | −487,776 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion | +2,277,515 | 2,277,515 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Purchase | +266,667 | $15.00 | $4.0M | 2,544,182 |
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series C Preferred Stock | −2,967,025 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series C-2 Preferred Stock | −4,238,607 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series D Preferred Stock | −6,781,770 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series E-2 Preferred Stock | −2,644,558 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series E-3 Preferred Stock | −2,293,829 | 0 | ||
| 2017-07-05 | Ambros Reinhard J. Director | Conversion · Series F Preferred Stock | −3,705,882 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion | +2,277,515 | 2,277,515 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Purchase | +266,667 | $15.00 | $4.0M | 2,544,182 |
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series C Preferred Stock | −2,967,025 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series C-2 Preferred Stock | −4,238,607 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series D Preferred Stock | −6,781,770 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series E-2 Preferred Stock | −2,644,558 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series E-3 Preferred Stock | −2,293,829 | 0 | ||
| 2017-07-05 | Novartis Bioventures Ltd 10% owner | Conversion · Series F Preferred Stock | −3,705,882 | 0 | ||
| 2017-06-28 | Dougherty Donald SVP & Chief Financial Officer | Grant or award · Stock Option (right to buy) | +140,887 | 140,887 |
Page 16 of 16 · 320 trades